Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ibandronic acid vs intravenous zoledronate in multiple myeloma
2005-003770-23Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ibandronic acid in multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoint: Proportion of patients with skeletal-related events. Started Mar 2006; status: completed.
02
Drugs
ibandronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-003770-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003770-23.